Nuveen Asset Management LLC Grows Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)

Nuveen Asset Management LLC raised its stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 16.7% during the second quarter, Holdings Channel reports. The fund owned 53,942 shares of the company’s stock after buying an additional 7,729 shares during the period. Nuveen Asset Management LLC’s holdings in Bolt Biotherapeutics were worth $834,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Bolt Biotherapeutics by 12.2% in the second quarter. BlackRock Inc. now owns 941,850 shares of the company’s stock valued at $14,561,000 after acquiring an additional 102,663 shares during the last quarter. Swiss National Bank purchased a new position in Bolt Biotherapeutics in the second quarter valued at about $433,000. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Bolt Biotherapeutics in the second quarter valued at approximately $11,125,000. Goldman Sachs Group Inc. raised its position in shares of Bolt Biotherapeutics by 93.3% in the second quarter. Goldman Sachs Group Inc. now owns 441,728 shares of the company’s stock valued at $6,829,000 after purchasing an additional 213,254 shares during the period. Finally, New York State Common Retirement Fund raised its position in shares of Bolt Biotherapeutics by 40.3% in the second quarter. New York State Common Retirement Fund now owns 11,508 shares of the company’s stock valued at $178,000 after purchasing an additional 3,308 shares during the period. Hedge funds and other institutional investors own 89.49% of the company’s stock.

BOLT has been the topic of several research reports. SVB Leerink lowered their price target on shares of Bolt Biotherapeutics from $35.00 to $33.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 10th. Jonestrading reaffirmed a “buy” rating and set a $45.00 target price on shares of Bolt Biotherapeutics in a report on Wednesday, November 24th. Finally, Zacks Investment Research raised shares of Bolt Biotherapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $41.00.

Bolt Biotherapeutics stock opened at $9.00 on Tuesday. The firm’s 50 day simple moving average is $11.89 and its 200 day simple moving average is $14.11. The company has a current ratio of 9.39, a quick ratio of 9.39 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $335.57 million and a PE ratio of -0.53. Bolt Biotherapeutics, Inc. has a 1-year low of $7.58 and a 1-year high of $43.07.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, November 8th. The company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.12. The firm had revenue of $0.75 million for the quarter, compared to the consensus estimate of $1.50 million. Research analysts forecast that Bolt Biotherapeutics, Inc. will post -2.62 earnings per share for the current year.

Bolt Biotherapeutics Profile

Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers.

Featured Article: What is the downside to momentum investing?

Want to see what other hedge funds are holding BOLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bolt Biotherapeutics, Inc. (NASDAQ:BOLT).

Institutional Ownership by Quarter for Bolt Biotherapeutics (NASDAQ:BOLT)